ARS Pharmaceuticals, Inc. SPRY
4.08
(0.07)
(1.69%)
as of 25 Sep
- Market cap
- $412.7M
- P/E
- 0.0×
Follow SPRY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.80 | 8.06 | 13.63 | 6.96 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.06) | (17.74) | (26.41) | (21.11) | |
P/B ratio |
63.58 | 13.01 | 10.05 | 6.73 | |
Price to Tangible BV |
0.00 | 16.92 | 11.51 | 7.47 | |
EV/Sales |
7.04 | 7.76 | 12.72 | 6.12 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.19) | (4.39) | (6.27) | (10.23) | |
EV/FCF |
(3.88) | (4.02) | (5.75) | (10.15) | |
Quick Ratio |
3.13 | 4.63 | 6.91 | 6.38 | |
Current Ratio |
3.48 | 4.94 | 7.28 | 6.66 | |
Net Debt/EBITDA |
(0.45) | 0.49 | 1.82 | 2.23 | |
Debt/Assets |
68.78% | 59.53% | 51.43% | 45.14% | |
Debt/Equity |
13.72 | 2.79 | 1.47 | 1.14 | |
Asset Turnover |
0.42 | 0.32 | 0.25 | 0.48 | |
Operating CF/Net income |
0.98 | 0.74 | 1.05 | 0.92 | |
Capex/Depreciation |
0.00 | 0.00 | 3.41 | 8.64 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
13.96% | 19.12% | 12.26% | 8.46% | |
Selling, General and Administrative Expense of Revenue |
230.49% | 318.35% | 213.46% | 230.00% | |
Intangible Assets out of Total Assets |
0.06 | 0.05 | 0.04 | 0.04 | |
Share Based Compensation of Revenue |
36.83% | 32.73% | 20.43% | 17.50% | |
Graham Net Nets |
(0.03) | 0.02 | 0.06 | 0.11 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(27.22%) | (25.03%) | (15.02%) | (8.06%) | |
Free Cash Flow Yield |
(26.66%) | (23.93%) | (16.25%) | (8.66%) | |
Revenue per Share |
0.34 | 0.23 | 0.29 | 0.33 | |
Operating CF per Share |
(0.61) | (0.45) | (0.44) | (0.48) | |
Capex per Share |
0.00 | 0.00 | (0.02) | (0.06) | |
Free Cash Flow per Share |
(0.61) | (0.45) | (0.46) | (0.54) | |
Cash per Share |
1.45 | 2.02 | 2.49 | 2.92 | |
Shareholders Equity per Share |
0.13 | 0.62 | 1.16 | 1.49 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.13 | 0.62 | 1.16 | 1.49 | |
Free Cash Flow |
(60.93) | (44.95) | (45.48) | (53.10) | |
Working Capital |
150.65 | 195.62 | 245.75 | 287.99 | |
Capital Expenditures |
— | — | (2.00) | (6.06) | |
Net Current Asset Value |
(25.47) | 18.97 | 71.50 | 113.72 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.07 | 0.19 | |
Net Profit Margin |
(185.34%) | (267.26%) | (147.05%) | (157.38%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
35.98 | 18.98 | 16.76 | 18.61 | |
Average Payables |
52.00 | 37.64 | 30.39 | 33.14 | |
Average Inventory |
10.21 | 8.04 | 6.79 | 4.25 | |
Average Assets |
281.48 | 307.44 | 339.40 | 295.20 | |
Average Common Equity |
102.42 | 145.14 | 185.53 | 174.32 |
Columns are period end dates